Asset
Lanifibranor
Inventiva S.A. American Depository Shares
Revenue
No revenue reported in loaded filings.
Clinical trials (4)
| NCT ID | Phase | Status | Start | Completion | Sponsor name | Title |
|---|---|---|---|---|---|---|
| NCT04849728 | phase3 | active_not_recruiting | 2021-08-19 | 2027-09-30 | Inventiva Pharma | A Phase 3 Study Evaluating Efficacy and Safety of Lanifibranor Followed by an Active Treatment Extension in Adult Patients With (NASH) and Fibrosis Stages F2 and F3 ( NATiV3 ) |
| NCT03008070 | phase2 | completed | 2017-02-07 | 2020-02-20 | Inventiva Pharma | Phase 2b Study in NASH to Assess IVA337 |
| NCT05232071 | phase2 | completed | 2022-06-29 | 2024-03-30 | Inventiva Pharma | Placebo-controlled, Proof-of-concept Study to Evaluate the Safety and Efficacy of Lanifibranor Alone and in Combination With SGLT2 Inhibitor EmpaGliflozin in patiEnts With NASH and Type 2 Diabetes Mellitus |
| NCT02503644 | phase2 | completed | 2015-10-29 | 2018-10-01 | Inventiva Pharma | Proof-of-concept Trial of IVA337 in Diffuse Cutaneous Systemic Sclerosis |
FDA applications (0)
This company has no applications containing this asset.